Volume 9, Number 11—November 2003
Research
Fluoroquinolones and the Risk for Methicillin-resistant Staphylococcus aureus in Hospitalized Patients1
Stephen G. Weber*
, Howard S. Gold*, David C. Hooper†, A.W. Karchmer*, and Yehuda Carmeli*
, Howard S. Gold*, David C. Hooper†, A.W. Karchmer*, and Yehuda Carmeli*
Table 2
Results of multivariable analysisa
| Risk factor |
MRSA cases |
MSSA cases |
|||
|---|---|---|---|---|---|
| OR (95% CI) |
p value |
OR (95% CI) |
p value |
||
| Primary covariates | |||||
| Levofloxacin |
3.38 (1.94 to 5.90) |
<0.001 |
0.69 (0.34 to 1.40) |
0.30 |
|
| Ciprofloxacin |
2.48 (1.32 to 4.67) |
0.005 |
0.47 (0.21 to 1.02) |
0.06 |
|
| Other covariates |
|||||
| Lung disease |
3.94 (2.43to6.40) |
<0.001 |
2.33 (1.43 to 3.81) |
<0.001 |
|
| Renal disease |
* |
1.98 (1.03 to 3.80) |
0.04 |
||
| Penicillin |
* |
1.78 (0.93 to 3.39) |
0.08 |
||
| Metronidazole |
1.92 (1.10 to 3.37) |
0.02 |
1.29 (0.65 to 2.56) |
0.46 |
|
| ICU stay |
5.33 (3.28 to 8.68) |
<0.001 |
4.60 (2.90 to 7.30) |
<0.001 |
|
| Emergent admission |
1.74 (1.09 to 2.78) |
0.02 |
1.90 (1.17 to 3.08) |
0.01 |
|
| Admission service |
|||||
| Medical |
* |
— |
— |
||
| Obstetrical |
* |
0.29 (0.08 to 1.05) |
0.06 |
||
| Surgical | * | 1.82 (1.12 to 2.97) | 0.02 | ||
aAll results adjusted for time at risk. Only variables significant (p < 0.05) on univariate analysis were included in final models. Several variables (indicated with an asterisk) met criteria for inclusion in the MSSA (methicillin-susceptible Staphylococcus aureus), but not the MRSA (methicillin-resistant Staphylococcus aureus) model. OR, odds ratio; CI, confidence interval; ICU, intensive care unit.
1This study was presented in part at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Sand Diego, California, September 2002.
Page created: January 21, 2011
Page updated: January 21, 2011
Page reviewed: January 21, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.